Moreover, MC2R antagonists could represent a valuable alternative to anticortisolic drugs in clinical management of ACTH-dependent hypercortisolism, essentially Cushing’s disease, when removal of the source of ACTH excess is impossible or incomplete. The gene discussed is POMC; the disease is adrenal gland hyperfunction.